# Xiushi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xiushi

- Industry: Biotechnology
- Headquarters: Nantong, China
- Website: www.xiushi-bio.com
- Latest round: Series A (Aug 15, 2025)
- Investors on record: 5

## About

Based in Nantong, China, and founded in 2020, Xiushi Biopharmaceutical (Nantong) Co., Ltd, trading as Xiushi, is a biomedical company that focuses on providing peptide drug biosynthesis solutions for industry partners. The core team is composed of technical experts in the fields of pharmaceutical engineering, fermentation engineering, and protein engineering. It was recognized as the National High-tech Enterprise. In August 2025, it closed a series A funding round from Arshine Group, Cui Capital, Daoxing Investment, Huatai Zijin Investment and Jinding Capital. The company's main business is the research and development, manufacturing, and sales of APIs and preparations for recombinantly expressed peptide or protein innovative drugs. Its products cover innovative drugs, APIs, pharmaceutical and green synthetic industrial enzymes, functional peptides, and protein products. Its biosynthesis strategy has been validated on several short peptides and complex cyclic peptides, which provides capacity building and cost advantages over traditional biological and chemical synthesis methods. The company’s revenue is generated by providing synthetic industrial enzymes, functional peptides, and protein products, etc.

## Funding rounds

- Series A, Aug 15, 2025 — Jinding Capital, Huatai Zijin Investment, Cui Capital, Daoxing Investment, Arshine Group
- Angel, Aug 7, 2023 — Cui Capital

## Investors

- Cui Capital (https://capitalatlas.ai/funds/cui-capital) — Angel, Series A
- Jinding Capital (https://capitalatlas.ai/funds/jinding-capital) — Series A
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A
- Daoxing Investment — Series A
- Arshine Group — Series A